The Series A round's proceeds will be used to fund clinical validation of the company’s first products for kidney transplantation, further development of its auto-immune biomarker pipeline, and its premarketing activities.
“I would like to thank Auriga Partners and the international group of investors who participated in this operation. This represents a substantial acknowledgement of our potential for developing innovative biomarkers, immunoprofiling services and companion diagnostic products. Our ambition is to change the standard of care in transplantation and auto-immune disorders by bringing true innovations to the market,” said Alain Huriez, MD, TcLand Expression's Chairman and CEO.
For more information on the companie, please visit: www.tcland-expression.com
